Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01290393 · ClinicalTrials.gov registry record
Post-marketing Study to Assess the Safety of CERVARIX When Used in the United States and in Canada
A clinical trial, sponsored by GlaxoSmithKline.
- Terminated
- Registry status
- 2
- Enrollment target
NCT01290393: Clinical Trial study, sponsored by GlaxoSmithKline.
NCT01290393 is a clinical trial that was terminated before completion, run by GlaxoSmithKline. The registered enrollment target is 2 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01290393 was terminated before completion, sponsored by GlaxoSmithKline.
- TERMINATED
- Registry status
- 2 participants
- Enrollment target
Study Summary
This study will assess the risk of spontaneous abortion during weeks 1-19 of gestation, and other pregnancy outcomes, in an Exposed vaccinated cohort, i.e. women with last menstrual period between 30 days before and 90 days after any dose of CERVARIX, when compared to a Non-exposed vaccinated cohort, i.e. women with last menstrual period between 120 days and 18 months after the last CERVARIX or GARDASIL dose.
Interventions
- OTHER Data collection
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2011-09-26 |
| Est. Completion | 2012-12-20 |
Why NCT01290393 stopped before completion
NCT01290393 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 2 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which Data collection is the first listed.
NCT01290393 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01290393 about?
NCT01290393 is a clinical study titled "Post-marketing Study to Assess the Safety of CERVARIX When Used in the United States and in Canada". This study will assess the risk of spontaneous abortion during weeks 1-19 of gestation, and other pregnancy outcomes, in an Exposed vaccinated cohort, i.e. women with last menstrual period between 30 days before and 90 days after any dose of CERVARIX, when compared to a Non-exposed vaccinated cohort...
What is the current status of trial NCT01290393?
This trial is currently terminated. The enrollment target is 2 participants. The study started on 2011-09-26. Estimated completion is 2012-12-20.
What interventions are being tested in trial NCT01290393?
The interventions under investigation include: Data collection (OTHER).
Who is sponsoring clinical trial NCT01290393?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI